Merck + Co., Inc.

Incyte Corporation

Bristol-myers Squibb Compnay

Dupont Pharmaceuticals Company

Gregory Franklin Hollis

George E Mark, Iii

Krishnaswamy Yeleswaram

Paul Smith

Timothy C Burn

Sunil K Gupta

Mayur D Patel

Kenneth Alves

Karyn O'Neil

Steven W Ludmerer

Krishna Vaddi

Dietmar A Seiffert

Jeffrey T Billheimer

Jordan S Fridman

Kevin R Oldenburg

Peggy Ann Scherle

Ira B Dicker

Steven M Friedman

Diana Benincasa

Thomas Dy Chung

Xiangdong Liu

Leah A Breth

Jennifer E Kochie

Henry J George

Jeannine M Hollis

Phillip C C Liu

Reid Huber

This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating gastrointestinal diseases or disorders such as ulcerative colitis.

JAK1 pathway inhibitors for the treatment of gastrointestinal disease

The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated.

Compositions, methods and kits relating to Her-2 cleavage

A specific locus in the genome of a murine host cell is identified which causes high levels of recombinant gene expression following stable integration, via homologous recombination, of the recombinant gene into the specific chromosomal locus. The selection of a favorable genome locus for the insertion and expression of a recombinant gene is disclosed, as are DNA vectors and host cells.

Homologous recombination antibody expression system for murine cells

Detection of patients at risk for developing integrin antagonist/agonist mediated disease states

An apparatus for holding liquid, such as a microtiter plate, in which a plurality of wells are formed. Each of the wells have side walls that intersect in an edge that defines the boundary between adjacent wells. The edge boundary prevents liquid from collecting between the wells, thereby causing all of the liquid applied to the plate to enter one of the wells. The microtiter plate can be formed from a material having a reflectance and/or fluorescence that is optimized for the particular application in which the microtiter plate will be used. Microtiter plates for use in fluorescence measurement applications are made from material having low fluorescence, such as a liquid crystal polymer, while microtiter plates for use in luminescence measurements are made from material having a high reflectance. Microtiter plates for spectrophotometric applications are made with wells having clear bottoms and opaque walls. Such clear bottomed wells can be made by incorporating a photobleachable dye into the plate material so as to render it essentially opaque and then irradiating the bottoms of the wells so as to render them transparent. Such wells can also be made by forming the plate from an essentially transparent material and then irradiating the sidewalls with a beam of light so as to render them essentially opaque.

Apparatus for holding small volumes of liquids

Contraceptive vaccine

The present invention is a series of synthetic virus-like particles useful in the characterization of human papillomavirus infection and assays employing the synthetic virus-like particles.

Synthetic HPV11 virus-like particles

The instant invention is drawn to a DNA encoding a sperm surface protein in substantially pure form selected from a human PH30 beta chain protein and a mouse PH30 beta chain proteins. Such proteins are useful as contraceptive vaccines in humans and mice respectively, and for identifying small molecules that will disrupt sperm-egg interaction and fertilization,

DNA encoding the mouse and human PH30 beta chain protein

The present invention relates to DNA molecules encoding a canine IgE and species-specific regions of the canine IgE constant region. The invention comprises the DNA molecules, proteins encoded by the DNA molecules, antibodies to the proteins, cells transformed by the DNA molecules, assays employing the transformed cells, compounds identified by the assays and kits containing the DNA molecules or derivatives thereof.

DNA encoding canine immunoglobulin E

The present invention relates to DNA molecules encoding a canine IgA and species-specific regions of the canine IgA constant region. The invention comprises the DNA molecules, proteins encoded by the DNA molecules, antibodies to the proteins, cells transformed by the DNA molecules, assays employing the transformed cells, compounds identified by the assays and kits containing the DNA molecules or derivatives thereof.

DNA encoding canine immunoglobulin A

Growing community of inventors

Westfield, NJ, United States of America

Gregory Franklin Hollis